16th week of 2020 patent applcation highlights part 24 |
Patent application number | Title | Published |
20200115422 | PEPTIDE LIGASE AND USE THEREOF - The present invention relates to a polypeptide that is capable of promoting the covalent conjugation of two peptide tags or linkers and in particular to a polypeptide comprising: a) an amino acid sequence as set forth in SEQ ID NO: 1; or b) an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 1, wherein said amino acid sequence comprises a glutamic acid at position 61 and one or more of the following: 1) proline at position 66; 2) proline at position 95; 3) glycine at position 96; and 4) valine at position 97, wherein the specified amino acid residues are at positions equivalent to the positions in SEQ ID NO: 1 and wherein said polypeptide is capable of promoting the formation of an isopeptide bond between the lysine residue at position 9 of SEQ ID NO: 2 and the asparagine residue at position 17 of SEQ ID NO: 3. | 2020-04-16 |
20200115423 | PURIFICATION OF PHYCOBILIPROTEINS - The present invention relates to a novel process for purifying phycobiliproteins, in particular acid-pH-resistant phycobiliproteins, the resulting phycobiliproteins, and the uses thereof. | 2020-04-16 |
20200115424 | CYSTINE KNOT SCAFFOLD PLATFORM - Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided. | 2020-04-16 |
20200115425 | COMPOSITIONS AND METHODS FOR REPROGRAMMING SOMATIC CELLS INTO INDUCED VASCULOGENIC CELLS - Disclosed herein are compositions and methods for directly reprogramming somatic cells into induced vasculogenic cells both in vitro and in vivo. These compositions and methods are useful for a variety of purposes, including the development of pro-angiogenic therapies. | 2020-04-16 |
20200115426 | CATIONIC INTRINSICALLY DISORDERED ANTIMICROBIAL PEPTIDES - The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms. | 2020-04-16 |
20200115427 | METHOD FOR DIAGNOSING OR TREATING PULMONARY FIBROSIS USING S100A13 PROTEIN - The invention is directed to a method for diagnosing and treating fibrosis, especially pulmonary fibrosis, associated with mutation of the S100A13 and S100A3 genes. Methods for detecting and distinguishing the mutant forms of these genes are disclosed and ways to compensate for loss of function or aberrant function of the mutated S100A13 or S100A3 proteins are disclosed. | 2020-04-16 |
20200115428 | METHODS AND COMPOSITIONS FOR INCREASING RED BLOOD CELLS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2020-04-16 |
20200115429 | MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - This invention provides for a fusion protein between an IL2αβγ Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2αβγ form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein. | 2020-04-16 |
20200115430 | HUMAN AMYLIN ANALOG POLYPEPTIDES AND METHODS OF USE - This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t | 2020-04-16 |
20200115431 | GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY - This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity. | 2020-04-16 |
20200115432 | AN ENGINEERED TWO-PART CELLULAR DEVICE FOR DISCOVERY AND CHARACTERISATION OF T-CELL RECEPTOR INTERACTION WITH COGNATE ANTIGEN - The present invention relates to a two-part device, wherein a first part is an engineered antigen-presenting cell system (eAPCS), and a second part is an engineered TCR-presenting cell system (eTPCS). | 2020-04-16 |
20200115433 | High-Affinity TCR For NY-ESO - Provided is a T cell receptor (TCR) having a property of binding to a SLLMWITQC-HLA A2 complex; and the binding affinity of the TCR to the SLLMWITQC-HLA A2 complex is at least twice that of a wild-type TCR to the SLLMWITQC-HLA A2 complex. Also provided is a fusion molecule of such a TCR with a therapeutic agent. Such a TCR can be used alone or in combination with a therapeutic agent so as to target tumour cells presenting the SLLMWITQC-HLA A2 complex. | 2020-04-16 |
20200115434 | ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF - The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs. | 2020-04-16 |
20200115435 | RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses Thereof - The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands. | 2020-04-16 |
20200115436 | 21-DAY DOSING REGIMEN FOR FUSION PROTEINS COMPRISING FACTOR IX AND HUMAN ALBUMIN FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF - The present invention relates to prophylactic dosing regimens with about 90-110 IU/kg long-acting factor IX (human FIX-human albumin) in dosing intervals of about three weeks (e.g., 21 days). | 2020-04-16 |
20200115437 | SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF - This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules. | 2020-04-16 |
20200115438 | SELECTIVE REDUCTION OF PROTEINS - The present invention provides a method for making uncapped cysteine protein preparations, including uncapped engineered cysteine antibody preparations. The methods include, inter alia, contacting a reducing agent with engineered cysteine antibody molecules, each of the antibody molecules having at least one capped engineered cysteine residue and at least one interchain disulfide bond and reacting the reducing agent with the antibody molecules under conditions sufficient to uncap engineered cysteine residues and form cap byproducts. The method also includes removing the cap byproduct during the reduction reaction. Substantially all of the interchain disulfide bonds present in the antibody molecules prior to reduction are retained following reduction. Antibody conjugates and methods for preparing antibody conjugates using uncapped antibody preparations are also described. | 2020-04-16 |
20200115439 | HUMAN IgE ANTIBODIES BINDING TO ASPERGILLUS ALLERGENS - The present disclosure is directed to antibodies binding to | 2020-04-16 |
20200115440 | Treatment of Fibrodysplasia Ossificans Progressiva - Methods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided. Such methods involve administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist or an activin receptor type 1 (ACVR1) antagonist. Antagonists include fusion proteins of one or more extracellular domains (ECDs) of ACVR2A, ACVR2B and/or ACVR1 and the Fc domain of an immunoglobulin heavy chain, and antibodies against ACVR2A, ACVR2B, ACVR1 or Activin A. | 2020-04-16 |
20200115441 | METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN - The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg | 2020-04-16 |
20200115442 | PROTEIN AQUEOUS SUSPENSION PREPARATION - Disclosed is a protein aqueous suspension preparation containing a protein and a polyamino acid, the protein and the polyamino acid having a surface charge in a buffer and forming a complex suspended in the buffer, wherein the absolute value of the difference between pH of the buffer and isoelectric point pI of the protein is in the range of from 0.5 to 4.0. Also disclosed are a method of preparing a protein aqueous suspension preparation and a prefilled syringe containing a concentrated protein aqueous suspension preparation. The protein can exhibit at least one of shaking stress resistance, fluidity enhancement, oxidation resistance, thermal stability, and aggregation inhibitory properties. | 2020-04-16 |
20200115443 | BI-FUNCTIONAL FUSION PROTEINS AND USES THEREOF - The present invention provides a bi-functional fusion protein simultaneously targeting the complement and the vascular endothelial growth factor (VEGF). The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting complement and VEGF related diseases. | 2020-04-16 |
20200115444 | METHODS FOR TREATING BONE GAP DEFECTS - The invention provides a method of enhancing bone gap defect healing involving administering a sclerostin inhibitor. | 2020-04-16 |
20200115445 | Methods of Suppressing Rheumatoid Arthritis Using an Anti-IL-6 Antibody - Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis. | 2020-04-16 |
20200115446 | PEDIATRIC OSTEOPOROSIS DRUG THAT DOES NOT CAUSE GROWTH DISORDER - An object of the present invention is to provide a pharmaceutical agent for the treatment and/or prophylaxis of pediatric osteoporosis without causing bone growth disorder in a subject to be medicated. A pharmaceutical composition for the treatment and/or prophylaxis of pediatric osteoporosis contains an antibody or a functional fragment thereof which binds to Siglec-15 and has activity of suppressing formation of osteoclasts and/or bone resorption by osteoclasts. | 2020-04-16 |
20200115447 | ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN - The present inventors have discovered that in living organisms that have received an antigen-binding molecule containing an antigen-binding domain whose binding activity to an antigen changes depending on ion concentration conditions and containing an FcRn-binding domain having FcRn-binding activity in a neutral pH range, immune responses to the antigen are induced. Furthermore, the present inventors have discovered that in living organisms that have received an antigen-binding molecule containing an antigen-binding domain whose binding activity to an antigen changes depending on ion concentration conditions and containing an FcRn-binding domain having FcRn-binding activity in a neutral pH range, immune responses to the antigen are induced, and also the antigen-binding molecule has cytotoxicity or antiproliferative action against cancer cells, foreign biological species, or such that express the antigen to which the antigen-binding molecule binds. | 2020-04-16 |
20200115448 | CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF - The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimeric signaling receptor (CSR) construct. The caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule, and the CSR comprises a ligand-binding domain that specifically binds to a target ligand and a co-stimulatory signaling domain capable of providing a stimulatory signal to the immune cell. Also provided are methods of making and using these cells. | 2020-04-16 |
20200115449 | NOVEL ANTI-CD3 ANTIBODIES - The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3ε domain. | 2020-04-16 |
20200115450 | SINGLE DOMAIN ANTIBODIES TARGETING CD1D - The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies. | 2020-04-16 |
20200115451 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTAGONIST OF PD-1 AND AN ANTI-CTLA4 ANTIBODY - The present invention relates to method for treating cancer comprising administering an antagonist of PD-1, e.g., anti-PD-1 antibody or antigen binding fragment thereof, and an anti-CTLA4 antibody or antigen binding fragment thereof, wherein the CTLA4 antibody or antigen binding fragment thereof is given at a fixed dose. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody and a dosage of an anti-CTLA4 antibody, and uses thereof. | 2020-04-16 |
20200115452 | ANTI-PHOSPHOTYROSINYLATED PD-1 ANTIBODIES AND USES THEREOF - The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes. | 2020-04-16 |
20200115453 | Anti-CD28 Humanized Antibodies Formulated for Administration to Humans - The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab′ antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks. | 2020-04-16 |
20200115454 | ANTI-PD-1 ANTIBODIES AND USES THEREOF - Provided are anti-PD-1 antibodies or fragments thereof. In various example, the antibodies or fragments thereof includes a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided. | 2020-04-16 |
20200115455 | COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS - The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells. | 2020-04-16 |
20200115456 | ANTIBODY, KIT COMPRISING THE SAME, AND USES THEREOF - Provided herein is a novel antibody exhibiting binding affinity and specificity to galectin-7. Also provided herein are methods for treating psoriasis or cancer in a subject by administering to the subject a drug selected with the aid of the present anti-galectin-7 antibody. | 2020-04-16 |
20200115457 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF - Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells. | 2020-04-16 |
20200115458 | INSULIN IMMUNOGLOBULIN FUSION PROTEINS - Disclosed herein are immunoglobulin fusion proteins comprising an insulin therapeutic peptide and an immunoglobulin region that targets the insulin therapeutic peptide to the liver of an individual in need thereof. Further disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject, for example, diabetes and diabetes related conditions. | 2020-04-16 |
20200115459 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES OR CONDITIONS - The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to NKG2D receptors present on the surface of cells underlying the disorders. | 2020-04-16 |
20200115460 | ANTI-IGF-I RECEPTOR ANTIBODY - The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these. | 2020-04-16 |
20200115461 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPIES - Provided herein are immune cells engineered to express one or more cell surface receptor polypeptides containing activatable antigen receptor polypeptides, and methods of use thereof for the treatment of diseases, including cancer. | 2020-04-16 |
20200115462 | ANTI-FACTOR D ANTIBODY VARIANT CONJUGATES AND USES THEREOF - The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. | 2020-04-16 |
20200115463 | ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF - Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. | 2020-04-16 |
20200115464 | Methods and Antibody Compositions for Tumor Treatment - The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders. | 2020-04-16 |
20200115465 | ANTIBODIES, BINDING FRAGMENTS, AND METHODS OF USE - The present disclosure relates to anti-SSEA4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to SSEA4 molecules and SSEA4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-SSEA4 antibodies and binding fragments induce ADCC or CDC effects in the targeted tumor cells and inhibit and/or reduce the cancer/tumor proliferation. The present disclosure also provides anti-SSEA4 antibodies and binding fragments thereof as a pharmaceutical composition for treating cancer. In addition, the anti-SSEA4 antibodies and binding fragments are useful in the diagnosis of cancers. | 2020-04-16 |
20200115466 | MONOCLONAL AND HUMANIZED ANTIBODIES TO A CANCER GLYCOPEPTIDE - The present invention discloses a mouse-human chimeric antibody preferably recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG on the surface of cancer cells, and the encoding sequences, wherein the monoclonal antibody having a light chain and a heavy chain. Moreover, the present invention provides humanized light and heavy chains, and the encoding sequences. The results of paired expression show that humanized antibodies also recognize the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG on the surface of cancer cells, and show the same specificity as the parental antibody. | 2020-04-16 |
20200115467 | PROTEIN BIOMARKER AND USES THEREOF - The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step. | 2020-04-16 |
20200115468 | FACTOR XI ANTIBODIES AND METHODS OF USE - The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same. | 2020-04-16 |
20200115469 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC MACULAR EDEMA - Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema. | 2020-04-16 |
20200115470 | T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA - Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma. | 2020-04-16 |
20200115471 | FINE CELLULOSE FIBER, PRODUCTION METHOD THEREOF, SLURRY, AND COMPOSITE - Provided are: a fine cellulose fiber that is superior in handling properties and that can suitably be used as a reinforcing material or the like for resin; a production method of the fine cellulose fiber; and a slurry and a composite comprising the fine cellulose fibers. The present invention pertains to fine cellulose fibers comprising a carbamate group. The degree of substitution with the carbamate group with respect to hydroxy groups in the fine cellulose fibers is preferably no less than 0.05 and no greater than 0.5. The present invention pertains to a slurry comprising the fine cellulose fibers, to a composite comprising the fine cellulose fibers and a resin, and to a production method of the fine cellulose fibers, comprising performing a heat treatment on a mixture of a plant raw material and urea or the like, and performing a miniaturization treatment of the plant raw material. | 2020-04-16 |
20200115472 | PHARMACEUTICAL COMPOUNDS COMPRISING MODIFIED FUCANS AND METHODS RELATING THERETO - Compositions and methods relating to fucan agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions or other diseases. | 2020-04-16 |
20200115473 | SURFACE MODIFICATION METHOD AND GASKET FOR SYRINGE - The present invention aims to provide a method for modifying a surface of a rubber vulcanizate and a gasket for syringes, which can provide a variety of functions, including sliding properties, liquid leakage resistance, and protein adsorption resistance. Provided is a surface modification method for modifying a surface of a rubber vulcanizate having a Shore A hardness of 55 to 90 as a modification target, the method including: step 1 of adding a silane compound to the surface of the modification target; and step 2 of reacting at least a fluoroalkyl group-containing silane compound to form a surface-modified layer. | 2020-04-16 |
20200115474 | METHOD FOR PRODUCING ORGANIC-INORGANIC HYBRID HYDROGEL - A method for producing an organic-inorganic hybrid hydrogel includes mixing an aqueous solution (A) containing a water-soluble organic monomer (a1) and a phosphonic acid-modified hectorite (a2), a polymerization initiator (B), and a polymerization promotor (C) with each other. The aqueous solution (A) has a viscosity of 1,000 mPa·s or less when stored at 50° C. for one week after preparation. The polymerization initiator (B) has a solubility of 50 g/100 ml or more in water at 20° C. The molar ratio [(B)/(a1)] of the polymerization initiator (B) to the water-soluble organic monomer (a1) is in the range of 0.01 to 0.1. The aqueous solution in the state immediately before being subjected to polymerization can be stored for a long term, and thus has excellent operation properties and has no restriction on the place where a hydrogel is produced, and therefore can be applied to various industrial uses. | 2020-04-16 |
20200115475 | Olefin Polymer, Preparation Method of the Same, and Film Using the Same - An olefin polymer capable of simultaneously satisfying excellent drop impact strength and transparency, a preparation method of the same, and a film using the same, can be provided. In an embodiment, an olefin polymer comprises a plurality of polymer chains, and satisfies the following conditions: i) each polymer chain of the plurality having an average number of short chain branches (SCBs) per 1000 carbon atoms of 20/1000C or more, wherein an SCB has C2 to C7 carbon atoms, ii) a molded film of the olefin polymer having a drop impact strength of 1500 g to 2400 g as measured in accordance with ASTM D1709A, wherein the molded film having a thickness of 100 μm, and iii) a molded film of the olefin polymer having a haze is 10% to 30% as measured in accordance with ASTM D1003, wherein the molded film having a thickness of 0.05 mm. | 2020-04-16 |
20200115476 | WATER-ABSORBENT RESIN, SOIL WATER-RETAINING MATERIAL, AND AGRICULTURAL/HORTICULTURAL MATERIAL - There is provided a water-absorbent resin that exhibits both high water absorbency and high water-discharge capacity. The water-absorbent resin of the present invention is a water-absorbent resin comprising a polymer of a water-soluble ethylenically unsaturated monomer, wherein when a cross-sectional image of the water-absorbent resin is observed using X-ray computed tomography, the water-absorbent resin has a ratio of the area of cavity portions (cavity area ratio) in the cross-sectional image of 5% or more, as calculated according to Equation (I): | 2020-04-16 |
20200115477 | CROSSLINKABLE POLYMER COMPOSITION AND CABLE WITH ADVANTAGEOUS ELECTRICAL PROPERTIES - A polymer composition includes a crosslinked polyolefin with improved DC electrical properties. Prior to crosslinking, the polymer composition includes a polyolefin and peroxide, in which the peroxide is in an amount of less than 35 mmol —O—O— per kilogram of the polymer composition. A cable can be surrounded by at least one layer including the polymer composition. | 2020-04-16 |
20200115478 | DIMETHYL-SILYL-BRIDGED-1-SUBSTITUTED-2-INDENYL METALLOCENE COMPLEXES FOR OLEFIN POLYMERIZATION - The invention relates to a metallocene complex according to formula A, wherein R1-R10 are independently selected from H, C1-C10 alkyl, C7-C20 Aralkyl groups, and C1-C10 alkoxy groups; wherein R11 is selected from methyl, ethyl, propyl, isopropyl, butyl, phenyl; wherein R1 and R2, R3 and R4, R4 and R5, R5 and R6, R7 and R8, R8 and R9, and/or R9 and R10 can be connected to form a ringstructure; wherein R0 is selected from a C1-C10 alkyl group or an aryl group wherein M is selected from Ti, Zr and Hf, X is an anionic ligand to M, z is the number of X groups and equals the valence of M minus 2. The invention further relates to a catalyst for preparing polyolefins, a process for polymerizing olefins and to polymers prepared by said catalyst system. | 2020-04-16 |
20200115479 | THERMOPLASTIC RESIN COMPOSITION, MANUFACTURING METHOD OF THERMOPLASTIC RESIN COMPOSITION, MOLDED PRODUCT AND MANUFACTURING METHOD OF MOLDED PRODUCT - A thermoplastic resin composition includes a graft copolymer (A) obtained by graft copolymerization of a monomer mixture (a) that includes at least an aromatic vinyl monomer (a1) and a (meth)acrylate monomer (a2), but does not practically contain a vinyl cyanide monomer (a3), in the presence of a rubbery polymer (r) having a refractive index of not lower than 1.510 and not higher than 1.520; and a vinyl copolymer (B). An acetone insoluble component (C) of the thermoplastic resin composition does not practically contain a vinyl cyanide monomer-derived unit. An acetone soluble component (D) of the thermoplastic resin composition contains the vinyl cyanide monomer-derived unit. The content of the vinyl cyanide monomer-derived unit is not lower than 2% by mass and not higher than 20% by mass relative to 100% by mass of the acetone soluble component (D). | 2020-04-16 |
20200115480 | COMPOSITION, OPTICAL FILM, POLARIZING PLATE, DISPLAY DEVICE, AND METHOD FOR PRODUCING COMPOSITION - A fluorine-containing copolymer composition includes repeating units derived from a fluorine-containing monomer represented by Formula (I) and from a monomer having at least two polymerizable groups, in which the latter is 3% by mass or more with respect to a total mass of the fluorine-containing copolymer, and the former is 15% by mass or more with respect to a total solid content in the composition, in the Formula (I), R | 2020-04-16 |
20200115481 | CURABLE AMINOPLAST ACRYLIC POLYOL COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND METHODS OF USE - A curable aminoplast acrylic polyol composition containing, calculated as solids on all the solids of the composition, (a) 50 to 85% by weight of at least one type of an acrylic polyol having a glass transition temperature Tg of from 15 to <50° C., an equivalent weight of hydroxyl groups on solids of from 330 to 420, a hydroxyl number on solids of from 120 to 180 mg KOH/g, and a number average of the molecular weight (Mn) of 1,000 to 3,000 Dalton, and (b) 15 to 50% by weight of an alkylated amino formaldehyde resin having a formaldehyde content in accordance with DIN EN ISO 11402 4.3 of less than 0.10%, and the amino compound is melamine, guanamine, benzoguanamine, urea, toluenesulfonamide and glycoluril, and the alkylated amino formaldehyde resin containing at least one type of alkyl groups having 1 to 12 carbon atoms, and (c) 0.5 to 5.0% by weight of at least one type of an acidic catalyst, together with a process of for preparation of the composition and methods of using the composition. | 2020-04-16 |
20200115482 | MIXTURE, POLYMER, OPTICAL FILM, OPTICALLY ANISOTROPIC PRODUCT, POLARIZING PLATE, DISPLAY DEVICE, ANTIREFLECTION FILM, AND PRODUCTION METHOD FOR MIXTURE - In a mixture, a content of a polymerizable compound (I) represented by the following Formula (I) is more than 0.2 times a content of a polymerizable compound (II) represented by the following Formula (II), where Ar | 2020-04-16 |
20200115483 | LIQUID CRYSTAL ELASTOMERS - Shape-programmable liquid crystal elastomers. The shape-programmable liquid crystal elastomers being synthesized by filling an alignment cell with liquid crystal monomers. The liquid crystal monomers align to a surface of the alignment cell and then are polymerized with a dithiol chain transfer agent. The alignment cell is configured to impose a director orientation on a portion of the shape-programmable liquid crystal elastomer. For some embodiments, liquid crystal elastomer laminates are prepared by arranging a plurality of liquid crystal elastomers such that a director orientation of each liquid crystal elastomer of the plurality is in registered alignment with an adjacent liquid crystal elastomer of the plurality. The arrangement is secured and the plurality of liquid crystal elastomers cured. | 2020-04-16 |
20200115484 | ACRYLOYL-BASED COPOLYMERS, TERPOLYMERS, AND USE AS HYDRATE INHIBITORS - Copolymers having General Formula (I): | 2020-04-16 |
20200115485 | Modified Conjugated Diene-Based Polymer and Rubber Composition Including the Same - A modified conjugated diene-based polymer, and more particularly, a modified conjugated diene-based polymer prepared by continuous polymerization and having remarkable processability, narrow molecular weight distribution and excellent physical properties, and a rubber composition including the same. | 2020-04-16 |
20200115486 | NITRILE GROUP-CONTAINING COPOLYMER RUBBER - A nitrile group-containing copolymer rubber containing 10 to 30 wt % of an α,β-ethylenically unsaturated nitrile monomer unit, 1 to 10 wt % of a fumaric acid monoester monomer unit, and 1 to 50 wt % of an α,β-ethylenically unsaturated monocarboxylic acid ester monomer unit and having an iodine value of 120 or less. | 2020-04-16 |
20200115487 | Water-Based Polyurethane Dispersions and Their Preparation - A prepolymer comprising acid functionality is made by a process comprising the step of contacting: (i) a di-isocyanate, (ii) a polyol containing an acid group, (iii) a polyol without an acid group, and (iv) a metal salt catalyst, the contacting conducted under reaction conditions and in a solvent consisting essentially of: (A) a dialkyl amide, and (B) optionally, an aprotic glycol ether. The prepolymer is useful in the preparation of water-based polyurethane dispersions, and certain of the solvent blends consisting essentially of a dialkyl amide and an optional aprotic glycol ether are azeotropic or pseudo-azeotropic. | 2020-04-16 |
20200115488 | THERMOSETTING COMPOSITION FOR FORMING COMPONENTS OF RIGID, GAS PERMEABLE LENSES - Disclosed herein are compositions and kits of materials for forming a component of a rigid gas permeable lens. An exemplary composition comprises a) an isocyanate terminated pre-polymer having an average of more than one isocyanate group per molecule and that is the reaction product of at least: i) an aliphatic diisocyanate, and ii) a diol component comprising a siloxane diol, a fluorinated diol, and/or a hydrophobic poly(alkylene oxide) diol, b) a hydrophobic poly(alkylene oxide) diol, and c) a monomeric polyol or a propoxylate thereof. The average number of isocyanate groups of the isocyanate terminated pre-polymer plus the average number of hydroxyl groups of the monomeric polyol, or a propoxylate thereof is equal to from 4.5 to 5.5. Kits of materials comprising elements that when combined form the composition are also disclosed. Further disclosed are articles and ocular devices comprising components formed from the compositions or kits. | 2020-04-16 |
20200115489 | ARTICLE COMPRISING EXPANDED TPU AND A COATING - The present invention relates to an article comprising expanded thermoplastic polyurethane as a substrate and a specific polyurethane urea coating on said substrate, as well as footwear, a process for producing the article and a use of a polyurethane urea solution. It has been found that a polyurethane urea coating comprising polycarbonate structural units strongly binds to expanded TPU substrates and maintains the intrinsic properties of the expanded TPU. | 2020-04-16 |
20200115490 | BIOCOMPATIBLE MATERIALS - A resin composition, the resin composition comprising a prepolymer ( | 2020-04-16 |
20200115491 | CURABLE COMPOSITION AND OPTICAL ELEMENT OBTAINED USING SAME - The present invention provides a curable composition excellent in curability and capable of forming, through light irradiation, a cured product excellent in light resistance, heat resistance, and transparency. The curable composition contains the following component (A), the following component (B), and the following component (C):
| 2020-04-16 |
20200115492 | IMPROVEMENTS IN RESIN CURATIVE SYSTEMS - There is provided a curative system for epoxy resins comprising an alkyl benzene diamine and an additional aromatic amine. There is also provided the use of an alkyl benzene diamine to enhance the performance of an aromatic amine as a curative for an epoxy resin in an infusion processes for the production of fibre reinforced composites; a curable epoxy resin composition containing a mixture of an epoxy resin and a curative system according to the invention; the use of a composition according to the invention as the curable resin in the production of fibre reinforced composites and/or in the production of fibre reinforced composites by infusion processes; a fibre reinforced composite comprising fibrous reinforcement material and a cured epoxy resin obtainable by curing a curable epoxy resin composition according to the invention, and a process for the production of fibre reinforced composites wherein a fibrous reinforcement material is laid up and a curable epoxy resin composition according to the invention is infused through the fibrous reinforcement material at a temperature of 80 to 130° C. and, once the composition has infused the fibrous reinforcement material, the temperature is raised to 150 to 190° C. | 2020-04-16 |
20200115493 | ALIPHATIC-AROMATIC POLYESTER HAVING ELEVATED WHITENESS INDEX - The present invention relates to an aliphatic-aromatic polyester having a whiteness index according to ASTM E 313-73 of at least 25, to a process for preparation thereof and to the use of the aliphatic-aromatic polyester for production of polyester fibers (PF). The present invention further relates to the polyester fibers (PF) comprising the aliphatic-aromatic polyester. | 2020-04-16 |
20200115494 | AROMATIC POLYCARBONATE RESIN, METHOD FOR PRODUCING SAME, AND AROMATIC DIHYDROXY COMPOUND - Provided is an aromatic polycarbonate resin that has not only high fluidity and thin-wall moldability but also excellent hue and transparency. The aromatic polycarbonate resin contains a structural unit derived from an aromatic dihydroxy compound and a carbonate-forming compound. A hydrolysate obtained by hydrolysis of the aromatic polycarbonate resin contains aromatic dihydroxy compounds represented by the following Formulae (2) and (3), and the content of the compound represented by Formula (2) is 250 ppm by mass or less with respect to that of the compound represented by Formula (3), wherein R | 2020-04-16 |
20200115495 | AROMATIC POLYCARBONATE OLIGOMER SOLID - The purpose of the present invention is to provide an aromatic polycarbonate oligomer solid with substantially reduced low-molecular-weight components, no or a substantially reduced amount of chlorine-containing compounds, high loose bulk density, and ease of handling. The aromatic polycarbonate oligomer solid contains a repeating unit represented by formula (1), has a weight average molecular weight of 500 to 10,000, low-molecular-weight components less than or equal to 5.0 area % measured with high-speed liquid chromatography, and a loose bulk density of greater than or equal to 0.30 g/cm | 2020-04-16 |
20200115496 | POLYCARBONATE RESIN COMPOSITION, MOLDED ARTICLE, POLYCARBONATE RESIN, AND END-CAPPING AGENT FOR POLYCARBONATE RESIN - A polycarbonate resin composition, a molded article, a polycarbonate resin, and an end-capping agent for polycarbonate resins are provided. The polycarbonate resin composition contains: a polycarbonate resin having a terminal structure represented by Formula (A) and having a viscosity average molecular weight from 1×10 | 2020-04-16 |
20200115497 | MONOEPOXIDE-MONOAMINE ADDUCTS AS WETTING AGENTS AND DISPERSANTS - The invention relates to epoxide-amine adducts obtainable by reaction of one or more primary amines (A) of general formula (I) | 2020-04-16 |
20200115498 | BIFUNCTIONAL POLY(ALKYLENEOXIDES) WITH AMINOALKYL AND UNSATURATED TERMINI AND DERIVATIVES THEREOF - A heterofunctional poly(alkyleneoxide) according to the invention contains a first polymer terminus containing a protected, unprotected, or derivatized amine or aminoalkyl functionality and a second polymer terminus containing an unsaturated functionality. Reaction products, derivatives, and methods of making these materials are also described. | 2020-04-16 |
20200115499 | POLY(ETHER KETONE KETONE) POLYMERS, CORRESPONDING SYNTHESIS METHODS AND POLYMER COMPOSITIONS AND ARTICLES MADE THEREFROM - Described herein are PEKK polymers having improved processability and improved crystallinity. It was surprisingly found that PEKK polymers formed using a specifically adapted nucleophilic synthesis route, in which different monomers are added in to the polymerization reaction at different points during the synthesis, had lower glass transition temperatures (“Tg”) and increased crystallinities, relative to PEKK polymers formed using traditional nucleophilic synthesis routes (“traditional PEKK polymers”). Furthermore, compared with PEKK polymers synthesized using an electrophilic synthesis routes, the PEKK polymers described herein and significantly lower halogen content. The synthesis routes includes a first heating of a first monomer blend in a reaction mixture, a subsequent first addition of a second monomer blend to the reaction mixture, and a second heating of the reaction mixture subsequent to the first addition. | 2020-04-16 |
20200115500 | PEBA-BASED COMPOSITION AND USE THEREOF FOR PRODUCING A FATIGUE-RESISTANT TRANSPARENT OBJECT - The present invention relates to a copolymer with a rigid polyamide block and a flexible polyether or polyester block, wherein said polyamide block is semicrystalline and consists of a copolyamide of W/Y.Z type, wherein:
| 2020-04-16 |
20200115501 | BRANCHED POLYIMIDE COMPOSITIONS, METHOD OF MANUFACTURE, AND USES THEREOF - A branched polyimide of the formula (I) wherein G is a group having a valence of t present in an amount 0.01 to 20 mol %, each Q is independently the same or different, and is a divalent C | 2020-04-16 |
20200115502 | COMPOSITIONS AND ARTICLES MADE FROM BRANCHED POLYETHERIMIDES - A branched polyimide of the formula (I) wherein G is a group having a valence of t, present in an amount of 0.01 to 10 mol %, or 0.05 to 5 mol %, or 0.1 to 4 mol %, or 0.1 to 3 mol %, each of Q, M, D, V, and R are as defined herein, q is 0 or 1, m is 0 or 1, d is 0 or 1, p is 1 or 2, t is 2 to 6, preferably 2 to 4, and each n is independently the same or different, and is 1 to 1,000, provided that the total of all values of n is greater than 4, wherein the branched polyimide has a zero-shear viscosity in a range from 500 to 15,000 Pa·s, a rheology ratio of 1.1 to 5, and a strain hardening ratio of 1 to 6. | 2020-04-16 |
20200115503 | CURABLE SILICONE RUBBER COMPOUNDS - Compositions of curable silicone rubber compounds containing at least one metal siloxane-silanol(-ate) compound, a method for preparing curable silicone rubber compounds containing at least one metal siloxane-silanol(-ate) compound, as well as the use of curable silicone rubber compounds containing at least one metal siloxane-silanol(-ate) compound as a sealant, an adhesive material, a potting compound and/or a coating agent. | 2020-04-16 |
20200115504 | SYNERGISTIC COMBINATIONS OF PLATINUM COMPOUNDS AND RHODIUM COMPOUNDS AS CATALYSTS IN HYDROSILYLATIONS - Composition for use as catalyst in hydrosilylations, comprising at least one platinum compound selected from the group consisting of Pt[(Me | 2020-04-16 |
20200115505 | POLYMERIZED IN-SITU HYBRID SOLID ION-CONDUCTIVE COMPOSITIONS - Provided herein are methods of forming solid-state ionically conductive composite materials that include particles of an inorganic phase in a matrix of an organic phase. The methods involve forming the composite materials from a precursor that is polymerized in-situ after being mixed with the particles. The polymerization occurs under applied pressure that causes particle-to-particle contact. In some embodiments, once polymerized, the applied pressure may be removed with the particles immobilized by the polymer matrix. In some implementations, the organic phase includes a cross-linked polymer network. Also provided are solid-state ionically conductive composite materials and batteries and other devices that incorporate them. In some embodiments, solid-state electrolytes including the ionically conductive solid-state composites are provided. In some embodiments, electrodes including the ionically conductive solid-state composites are provided. | 2020-04-16 |
20200115506 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE - The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, thereby allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed. | 2020-04-16 |
20200115507 | SHAPE-PRESERVING POLYMERIC REPLICATION OF BIOLOGICAL MATTER - The present invention relates to a method of forming silica nanolayers on or within a biological sample, thereby capturing structural details that are present in the sample. The resultant silica composite or silica replica, in turn, can be employed as a template for a replica having those structural details captured in a polymer. Also provided herein are synthetic constructs including a polymeric replica, which can have any useful feature (e.g., oxygen-binding capacity). | 2020-04-16 |
20200115508 | Preparation Method of Super Absorbent Polymer - The present disclosure relates to a preparation method of a super absorbent polymer containing a novel cross-linking agent compound. The preparation method of a super absorbent polymer of the present disclosure can provide a super absorbent polymer exhibiting excellent absorption properties and an excellent deodorizing effect by including a cross-linking agent with a novel structure. Therefore, according to the present disclosure, since a separate additive for a deodorizing property is not required, processability and economic efficiency of the manufacturing process can be improved. | 2020-04-16 |
20200115509 | RESIN POWDER, METHOD FOR ITS PRODUCTION, COMPOSITE, MOLDED PRODUCT, METHOD FOR PRODUCING CERAMIC MOLDED PRODUCT, METAL LAMINATED PLATE, PRINTED CIRCUIT BOARD AND PREPREG - To provide a method capable of producing, by means of mechanical pulverization, a resin powder having a high bulk density and an average particle size of at most 50 μm from resin particles containing a fluorocopolymer as the main component and having a melting point of from 260 to 320° C., such as PFA. The method is to obtain a resin powder having an average particle size of from 0.02 to 50 μm by subjecting resin particles (A) having an average particle size of at least 100 μm to mechanical pulverization treatment. The resin particles (A) is made of a material (X) having a fluorocopolymer (X1) as the main component; and said fluorocopolymer (X1) has a unit (1) based on a monomer containing at least one type of functional group selected from the group consisting of a carbonyl group-containing group, a hydroxy group, an epoxy group and an isocyanate group, and a unit (2) based on tetrafluoroethylene, and has a melting point of from 260 to 320° C. | 2020-04-16 |
20200115510 | COATING POWDERED POLYMER WITH A WATER-SOLUBLE DYE AS AN INDICATOR FOR POLYMER HYDRATION STATE - A method for determining hydration of a polymer includes mixing a water-soluble, powdered dye with a powdered polymer and introducing the mixed water-soluble, powdered dye and powdered polymer into a water-based fluid. Full hydration of the powdered polymer is determined when the mixed water-soluble, powdered dye, powdered polymer and water-based fluid comprises substantially no internal optical contrast. | 2020-04-16 |
20200115511 | A METHOD FOR PREPARING MASTERBATCH AND FIBER WITH COMPOSITE ANTIBACTERIAL AND DEODORIZING FUNCTIONS - The present invention provides a method for preparing a masterbatch and fibers with composite antibacterial and deodorizing functions including surface modifying a copper powder; functionalizing resin powder; and preparing the composite antibacterial and deodorizing masterbatch. The present invention provides a new antibacterial compounding mechanism to prepare new antibacterial and deodorizing masterbatch and fibers which have permanent antibacterial function, and the mechanical properties thereof can reach the standard of general fibers; fully meets the requirements of various weaving; the cost thereof is comparable to that on antibacterial post-treatment; and the pollution is reduced. The present invention can increase the export volume and additional value of the textiles. | 2020-04-16 |
20200115512 | CROSS-LINKED RUBBER AND PRODUCTION METHOD THEREFOR - Provided is a cross-linked rubber that can improve long-term sealing properties of a seal member in high-temperature and high-pressure environments. The cross-linked rubber is obtained through cross-linking of a cross-linkable rubber composition containing a fluororubber, carbon black, one or more carbon nanotubes, and an organic peroxide cross-linker, and has a 50% modulus of 5 MPa or more, a compression set (230° C., 500 hours) of 80% or less, and a rate of change of elongation at break between before and after a heat aging test (230° C., 72 hours) of not less than −10% and not more than 10%. | 2020-04-16 |
20200115513 | NANOSTRUCTURED BACTERIA-RESISTANT POLYMER MATERIALS - Methods for creating nanostructured surface features on polymers and polymer composites involve application of low pressure during curing of solid polymer material from a solvent solution. The resulting nanoscale surface features significantly decrease bacterial growth on the surface. Polymer materials having the nanoscale structuring can be used in implantable medical devices to inhibit bacterial growth and infection. | 2020-04-16 |
20200115514 | FIBER SIZING AGENT, FIBER MATERIAL, MOLDING MATERIAL AND MOLDING - A fiber sizing agent includes: a vinyl ester resin (A) having an alkoxy polyoxyalkylene structure and a urethane bond; and an aqueous medium. The fiber sizing agent has excellent fiber sizing properties for various fibers such as glass fibers and carbon fibers. A molded article obtained from a molding material including the fiber sizing agent is excellent in various physical properties such as bending strength, compressive strength, and interlaminar shear strength, and thus can be used, for example, for an automobile member, an aircraft member, a windmill member, and an industrial member. | 2020-04-16 |
20200115515 | RESIN-METAL COMPOSITE MEMBER FOR TIRE, AND TIRE - A resin-metal composite member for a tire, the member including a metal member ( | 2020-04-16 |
20200115516 | Fiber Polymer Composite - The claimed material relates to a fiber and polymer composite having enhanced modulus, viscoelastic and rheological properties. | 2020-04-16 |
20200115517 | Non-Polar Ethylene-Based Compositions with Triallyl Phosphate for Encapsulant Films - An encapsulant film is made from a composition comprising (A) a non-polar ethylene-based polymer having a density of 0.850 g/cc to 0.890 g/cc; (B) an organic peroxide; (C) a silane coupling agent; and (D) a co-agent comprising triallyl phosphate. | 2020-04-16 |
20200115518 | Method for Providing Objects with a Protective Coating of Silicone Elastomer - The present invention relates to a method for providing objects with a protective coating of silicone elastomer. The present invention further relates to silicon coated objects obtainable by the method of present invention. The method of present invention can be used for the thin, protective and durable coating and production of environmental friendly consumer products. | 2020-04-16 |
20200115519 | ORGANIC SUBSTRATES HAVING IMPROVED WEATHERABILITY AND MAR RESISTANCE - Provided are polymeric materials that demonstrate excellent mar resistance as well as clarity and weatherability as well as processes for their manufacture. In some aspects a thermoplastic material includes a light stabilizer at or within the surface of the material and a mar resistant coating material layered directly on the surface, optionally without any intermediate primer layer, adhesion promotion layer or material, or other functional layer. | 2020-04-16 |
20200115520 | HEAT SHRINKABLE FILM AND METHOD FOR REPRODUCING POLYESTER CONTAINER USING SAME - Embodiments relate to a heat shrinkable film and a process for regenerating a polyester container using the same. The heat shrinkable film comprises a copolymerized polyester resin comprising a diol component and a dicarboxylic acid component and has a heat shrinkage rate of 30% or more in the main shrinkage direction upon thermal treatment at a temperature of 80° C. for 10 seconds and a melting point of 190° C. or higher as measured by differential scanning calorimetry. It not only solves the environmental problems by improving the recyclability of the polyester container, but also is capable of enhancing the yield and productivity. | 2020-04-16 |
20200115521 | FILM WITH LOW HEAT CONDUCTIVITY, REDUCED DENSITY AND LOW SOLAR ABSORPTION - The invention relates to a dark, flat element, preferably a plastic, lacquer coating or fiber material, having reduced density, low heat conductivity and low solar absorption. The flat element has a relatively high reflection infrared range of the electromagnetic spectrum reduce heating by sunlight in the near infrared dark tinting in the visible range. Low density conductivity are obtained inter alia by inserting in the near in order to area despite and low heat light filling materials into the flat element. Said flat element can be used in places where surfaces are dark tinted for aesthetic or technical reasons but should not heat up in sunlight and should give off little heat when touched by hand or by other parts of the body. Other areas of application include surfaces which should have a heat insulating effect in addition to the above-mentioned characteristics. | 2020-04-16 |